Pfizer and Head of New Drug Division Part Ways

Dec 17, 2013


Amy Schulman, named to head one of Pfizer’s three new drug units starting next month, will instead leave the company.

Schulman, a deputy to Chief Executive Officer Ian Read and Pfizer’s general counsel, was chosen in July to lead one of the businesses as the New York-based company reorganizes ahead of a potential breakup. Albert Bourla, a 20-year Pfizer veteran, will now head the unit, which handles vaccines, oncology and consumer health products, Pfizer said in a statement today. The company didn’t give a further reason for Schulman's departure or say she was leaving for another job. Read the full story.